Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Randomized, Open-labeled Trial to Evaluate the Immunogenicity and Safety of One or Two Doses of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain in Adults in Hong Kong

NCT05411471 is registered in ClinicalTrials.gov with Sinovac Biotech (Hong Kong) Limited as lead sponsor.

NCT NCT05411471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05411471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Randomized, Open-labeled Trial to Evaluate the Immunogenicity and Safety of One or Two Doses of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain in Adults in Hong Kong
Lead sponsor
Sinovac Biotech (Hong Kong) Limited
Phase
Phase 2
Overall status
Completed
Start date
June 8, 2022
Completion date
June 25, 2023
Enrollment
221 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19